Written by 
Anchiy
- Eli Lilly (NYSE:LLY) and privately held Incyclix Bio have agreed to work on a clinical trial together evaluating the former’s Verzenio (abemaciclib) with the latter’s INX-315 and fulvestrant as a potential treatment for HR+/HER2- breast cancer.
- Terms call for Lilly